Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
| Title: | Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” |
|---|---|
| Authors: | Andreas Schneeweiss; Johannes Ettl; Diana Lüftner; Matthias W. Beckmann; Erik Belleville; Peter A. Fasching; Tanja N. Fehm; Matthias Geberth; Lothar Häberle; Peyman Hadji; Andreas D. Hartkopf; Carsten Hielscher; Jens Huober; Eugen Ruckhäberle; Wolfgang Janni; Hans Christian Kolberg; Christian M. Kurbacher; Evelyn Klein; Michael P. Lux; Volkmar Müller; Naiba Nabieva; Friedrich Overkamp; Hans Tesch; Elena Laakmann; Florin-Andrei Taran; Julia Seitz; Christoph Thomssen; Michael Untch; Pauline Wimberger; Rachel Wuerstlein; Bernhard Volz; Diethelm Wallwiener; Markus Wallwiener; Sara Y. Brucker |
| Source: | Breast, Vol 55, Iss , Pp 138-139 (2021) |
| Publisher Information: | Elsevier |
| Publication Year: | 2021 |
| Collection: | Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | http://www.sciencedirect.com/science/article/pii/S0960977620302472; https://doaj.org/toc/1532-3080; https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131 |
| DOI: | 10.1016/j.breast.2020.12.007 |
| Availability: | https://doi.org/10.1016/j.breast.2020.12.007; https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131 |
| Accession Number: | edsbas.7847E418 |
| Database: | BASE |